Lauren White
Fortune : 121 909 $ au 31/05/2026
Fortune : 121 909 $ au 31/05/2026
Lauren A. White is currently Chief Financial Officer at Seaport Therapeutics, Inc. since 2024.
Former roles include Chief Financial Officer & Senior Vice President at ImmunoGen, Inc. from 2023 to 2024, Treasurer, Chief Financial & Accounting Officer at C4 Therapeutics, Inc. from 2021 to 2023, and VP, Global Head-Business Planning & Analysis at Novartis Institutes for Biomedical Research, Inc. Education includes an MBA from Harvard Business School conferred in 2007 and an undergraduate degree from Wallace E Carroll School of Management conferred in 2000.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
0,01 % | 04/05/2026 | 6 702 ( 0,01 % ) | 121 909 $ | 31/05/2026 |
| Sociétés | Poste | Début |
|---|
| Sociétés | Poste | Fin |
|---|---|---|
| IMMUNOGEN, INC. | Directeur Financier/CFO | 01/01/2024 |
| C4 THERAPEUTICS, INC. | Directeur Financier/CFO | 15/09/2023 |
Novartis Institutes for Biomedical Research, Inc.
Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Conducts biomedical researches | Corporate Officer/Principal | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 5 |
|---|---|
ImmunoGen, Inc.
ImmunoGen, Inc. BiotechnologyHealth Technology Develops anticancer therapeutics | Health Technology |
Novartis Institutes for Biomedical Research, Inc.
Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Conducts biomedical researches | Commercial Services |
Harvard Business School
Harvard Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Wallace E Carroll School of Management
Wallace E Carroll School of Management Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
C4 Therapeutics, Inc.
C4 Therapeutics, Inc. BiotechnologyHealth Technology Develops targeted protein degradation therapeutics for the treatment of cancer | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national